8-OH-DPAT, a selective 5-HT1A agonist, produced a hypothermic response
in mice at a dosage of 0.5 mg/kg. Administration of corticosterone-21
-acetate (0.5, 5 and 50 mg/kg, daily for 3 and 10 days) produced a dos
e-dependent attenuation of this hypothermic response in mice. When all
controls and corticosterone treated mice were retested, 14 days after
initial testing, they did not differ in the hypothermic responses ind
uced by 8-OH-DPAT. Mice treated with aldosterone (50 mg/ kg), dexameth
asone (50 mg/kg) and the specific type 2 corticosteroid receptor agoni
st, ydroxy-21-methyl-17a-pregna-1,4,6-trien-20-yn-3-on (RU26988, 30 mg
/kg) for 10 days, did not differ from vehicle treated controls in the
hypothermic response to 8-OH-DPAT. Mice administered corticosterone-21
-acetate (30 mg/kg, daily) for 10 days displayed a motor behavioural s
yndrome, which was not seen in controls, when injected with 5-hydroxyt
ryptophan (5-HTP, 100 mg/kg) 15 min after the injection of carbidopa (
25 mg/kg). This was significantly decreased by pretreatment with the 5
-HT1A receptor antagonist 2-methoxyphenyl)-4-(4-phthalimidobutyl)-pipe
razine (NAN-190 5 mg/kg, 30 min prior to administration of carbidopa).
Taken together, this evidence is compatible with a specific corticost
erone induced facilitation of 5-HT release due to attenuation of inhib
itory 5-HT1A autoreceptor function.